WASHINGTON (Reuters) – A potentially fatal hog virus, porcine epidemic diarrhea, has been found in the United States for the first time, government and private industry officials said on Friday, posing a new threat for the country’s struggling pork producers.
NEW YORK (Reuters Health) – A review of past research finds that fever-reducing drugs have no effect on the speed of children’s recovery from an infection, contrary to the fears of some doctors and parents.
NEW YORK (Reuters) – The long-awaited, controversial new edition of the bible of psychiatry can be characterized by many numbers: its 947 pages, its $ 199 price tag, its more than 300 maladies (from “dependent personality disorder” and “voyeuristic disorder” … Continue reading
STOCKHOLM (Reuters) – Sweden’s Recipharm has hired UBS to advise on either a partial sale of the pharmaceutical company or a listing on the Stockholm exchange, a source close to the process told Reuters on Thursday.
WASHINGTON (Reuters) – The Obama administration on Wednesday announced a $ 1 billion initiative to fund innovations in federal healthcare programs aimed at cutting costs while improving the health results.
FRANKFURT (Reuters) – German drugmaker Bayer said on Wednesday it initiated a Phase III trial of its potential blockbuster drug regorafenib in patients with advanced liver cancer.
WASHINGTON (Reuters) – Americans at high risk for heart problems who have been told for years to sharply cut salt from their diet may not actually benefit from ultra-low sodium diets and could even face some harm, an independent panel … Continue reading
RIYADH (Reuters) – Saudi Arabia has confirmed four new cases of the SARS-like novel coronavirus in its Eastern Province, state media reported late on Monday, citing the health ministry.
(Reuters) – Medical device maker C.R. Bard Inc will pay about $ 48.3 million to resolve allegations it made illegal payments to hospitals and physicians to entice them to buy its radiation treatment for prostate cancer, the Justice Department said.
(Reuters) – Indian generic drugmaker Ranbaxy Laboratories Ltd pleaded guilty on Monday to felony charges related to drug safety and will pay $ 500 million in civil and criminal fines under the settlement agreement with the U.S. Department of Justice.